A HER2 antibody is a lab-made protein designed to latch onto a specific target on cancer cells called HER2 (human epidermal growth factor receptor 2), blocking the signals that tell those cells to grow and divide. HER2 is overexpressed in roughly 20–30% of breast cancers and a similar share of certain stomach cancers, and tumors that overproduce it tend to be more aggressive, with higher recurrence rates and worse survival if left untreated.1PubMed Central. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy The antibodies used against HER2 come in several forms, from “naked” antibodies that block signaling and recruit immune cells, to antibody-drug conjugates that deliver a toxic payload directly inside the cancer cell. Understanding how each type works helps explain why HER2-targeted therapy has been one of the most successful stories in modern oncology.
What HER2 Actually Does in Normal and Cancer Cells
HER2 is a receptor protein that sits on the surface of many cell types. In healthy tissue, it plays a routine role in cell growth, repair, and survival. The receptor belongs to a family of four related proteins (HER1 through HER4). What makes HER2 unusual is that it has no known ligand of its own, meaning no specific signaling molecule docks into it to switch it on. Instead, HER2 pairs up with its family members after they have been activated by their own ligands, forming two-receptor units called dimers.2PubMed. HER2 in breast cancer: a review and update When HER2 joins one of these pairs, it amplifies the downstream signal, triggering cascades inside the cell that promote growth and prevent programmed cell death.
In cancer, something goes wrong at the genetic level. The HER2 gene, located on chromosome 17, gets amplified, meaning the cell ends up with too many copies of it. That gene amplification leads to overexpression of the HER2 protein on the cell surface. Instead of a normal number of receptors, a HER2-positive cancer cell can display vastly more. With so many HER2 molecules available, more dimers form, signaling becomes much stronger than normal, and the cell becomes hypersensitive to growth signals.3PubMed. The basic biology of HER2 The two main signaling highways activated are the MAPK pathway and the PI3K pathway, both of which drive cells to multiply and resist death signals.4PubMed Central. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review This is what makes HER2-positive cancers so aggressive, and also what makes them vulnerable to targeted antibodies.
How Naked Antibodies Block HER2 Signaling
The first HER2 antibody to reach patients was trastuzumab, approved in 1998. It is sometimes called a “naked” antibody because, unlike newer designs, it carries no attached drug or toxin. Trastuzumab binds to a specific region on the outside of the HER2 receptor and interferes with signaling in several ways at once.5PubMed Central. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma It physically blocks the receptor from pairing up with its partners, preventing dimer formation. It can also trigger the cell to pull HER2 receptors off the surface and break them down internally, reducing the total number of receptors available. And it interferes with signals that would normally keep the cell alive and dividing.
But trastuzumab does something beyond simple blockade. The antibody’s tail end, called the Fc region, acts as a flag for the immune system. Natural killer (NK) cells patrol the body looking for cells tagged by antibodies, and when they find one coated in trastuzumab, they attack. This process, called antibody-dependent cell-mediated cytotoxicity (ADCC), is a substantial part of how trastuzumab works in patients.6PubMed Central. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era In short, the antibody fights the tumor from two directions: it starves the cancer cell of growth signals while simultaneously painting it as a target for immune destruction.
Why Two Antibodies Can Be Better Than One
Pertuzumab, a second naked HER2 antibody, binds to a completely different spot on the HER2 receptor than trastuzumab. While trastuzumab mainly blocks one type of receptor pairing, pertuzumab is particularly good at preventing HER2 from forming heterodimers with HER3, a combination that is one of the most potent drivers of cancer cell survival. Used together, the two antibodies block HER2 from multiple angles, and the combination produces greater antitumor activity than either agent alone.7PubMed Central. Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
The immune benefit stacks too. Studies have shown that tumor cell killing through ADCC increases when both trastuzumab and pertuzumab are present, compared to either antibody on its own, because NK cells encounter more antibody flags on the cell surface.8PubMed Central. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells This dual blockade is now standard of care for HER2-positive breast cancer in both early and advanced settings.6PubMed Central. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Antibody-Drug Conjugates and the Trojan Horse Strategy
Some of the most exciting advances in HER2-targeted therapy have come from antibody-drug conjugates, or ADCs. These are essentially antibodies with a potent cell-killing chemical attached by a molecular linker. The idea is to use the antibody as a delivery vehicle, steering the toxin straight to cancer cells while sparing healthy tissue.
The first HER2 ADC to reach patients was ado-trastuzumab emtansine, known as T-DM1. Once T-DM1 binds to HER2 on the cell surface, the cancer cell engulfs the whole complex. Inside the cell, the antibody is broken down by digestive enzymes in a compartment called the lysosome, and the attached toxin (a derivative of the chemotherapy agent DM1) is released, killing the cell from within.9PubMed. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer Research into T-DM1’s internalization pathway has shown that the process depends on specialized structures in the cell membrane called lipid rafts, and that it ramps up significantly within the first 12 hours after binding.10PubMed Central. Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
A newer ADC, trastuzumab deruxtecan (T-DXd), has expanded the reach of HER2-targeted therapy dramatically. T-DXd carries a different type of payload and uses a cleavable linker that releases the drug not only inside the cancer cell but also into the surrounding area. This “bystander killing” effect means that nearby cancer cells, even ones with lower HER2 levels, can be hit by the freed toxin. Research has identified an enzyme called cathepsin L, released by tumor cells into the surrounding environment, as a key player in cleaving the linker and enabling this extracellular drug release.11Cancer Immunology Research. Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer This bystander effect is one reason T-DXd has shown activity even in tumors classified as “HER2-low,” a category that was previously considered untreatable with HER2-targeted drugs.
How Doctors Determine If a Tumor Is HER2-Positive
None of these therapies work unless the cancer actually overexpresses HER2, so accurate testing is essential. The standard approach starts with immunohistochemistry (IHC), which stains a tissue sample to show how much HER2 protein is present on the cell surface. Results are scored from 0 to 3+. A score of 3+ means the tumor is clearly HER2-positive. A score of 0 or 1+ means it is negative. When the result falls in the middle (2+, or “equivocal”), a second test using a technique called in situ hybridization (ISH) is performed to count the actual number of HER2 gene copies in the tumor cells.12PubMed Central. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Getting this classification right is more complicated than it sounds. Guidelines from ASCO and the College of American Pathologists divide ISH results into multiple groups based on both the HER2-to-chromosome-17 ratio and the absolute number of HER2 gene copies per cell. Cases that fall cleanly into the highest category (high ratio and high gene copy number) correlate strongly with IHC 3+ results. But tumors in the intermediate and borderline zones can be ambiguous, and their clinical behavior is harder to predict.13PubMed Central. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH) The emergence of the “HER2-low” category, meaning tumors with an IHC score of 1+ or 2+ without gene amplification, has added another layer. These tumors were once considered simply HER2-negative, but drugs like T-DXd have shown meaningful activity against them, prompting a rethinking of who qualifies for HER2-targeted therapy.
HER2 Antibodies Beyond Breast Cancer
While breast cancer is where HER2 antibodies were born, the target shows up in other tumor types too. About 20% of gastric or gastroesophageal junction cancers overexpress HER2, and trastuzumab became the first targeted therapy approved for that setting when combined with chemotherapy.14PubMed Central. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer The track record in stomach cancer has been rockier than in breast cancer, though. Several agents that worked well in breast tumors, including pertuzumab and T-DM1, failed to improve survival in gastric cancer trials, suggesting that HER2 biology differs between the two tumor types. The newer ADC trastuzumab deruxtecan has shown more promise and is pushing gastric cancer treatment into a new phase.15PubMed Central. Challenges and future of HER2-positive gastric cancer therapy
Non-small-cell lung cancer (NSCLC) is another frontier. HER2 alterations in lung cancer can take the form of overexpression, gene amplification, or specific mutations in the HER2 gene itself, and these different alteration types may respond differently to therapy.16PubMed Central. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies Trastuzumab deruxtecan has been evaluated in NSCLC patients with HER2 overexpression or mutations in the DESTINY-Lung01 trial.17PubMed. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01) As trials continue, defining which HER2 alteration predicts the best response will be critical for selecting the right patients.
When HER2 Antibodies Stop Working
Resistance is the central challenge of HER2-targeted therapy. Some patients do not respond to trastuzumab from the start (primary resistance), while others respond initially but eventually relapse (acquired resistance). The mechanisms behind resistance are varied and not fully mapped out. Tumors can activate alternative signaling pathways that bypass HER2 altogether, reduce the amount of HER2 on the cell surface, or develop mutations in the downstream signaling molecules that keep growth signals firing regardless of what happens at the receptor.18PubMed Central. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
This is part of why the field has developed so many different types of HER2-targeted agents. When a naked antibody stops working, an ADC might still be effective because it delivers a toxic payload that kills the cell through a different mechanism. When one ADC fails, another with a different payload or linker chemistry may succeed. And newer designs like bispecific antibodies, such as zanidatamab, which binds two separate spots on HER2 simultaneously with a single molecule, offer yet another angle of attack.19PubMed. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers The evolving arsenal means that even when one therapy fails, the story is not necessarily over.
Side Effects That Matter Most
HER2 antibodies are far better tolerated than traditional chemotherapy, but they are not side-effect-free. The most well-known concern with trastuzumab is cardiotoxicity. HER2 is expressed at low levels in heart muscle cells, and blocking it there can interfere with cardiac function. In one retrospective study at a single oncology center, about a quarter of patients on HER2-targeted therapy showed some degree of cardiac effects, with roughly one in ten developing symptomatic heart failure. Higher body mass index, older age, and pre-existing high blood pressure were the strongest risk factors.20PubMed Central. Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center In practice, patients on trastuzumab undergo regular cardiac monitoring, and the heart damage is often reversible if caught early, which distinguishes it from the more permanent cardiac injury caused by some older chemotherapy drugs.
For the newer ADCs, a different concern has emerged: interstitial lung disease (ILD), a form of lung inflammation. Studies in monkeys showed that T-DXd at high doses caused lung inflammation with features resembling ILD seen in patients, including immune cell infiltration and mild scarring. The drug accumulated in alveolar macrophages, immune cells deep in the lungs, in a pattern unrelated to HER2 expression in lung tissue, suggesting that the uptake was nonspecific.21PubMed Central. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys Research into the mechanism has shown that ADCs accumulate in these macrophages in a dose-dependent manner regardless of target antigen expression, releasing their toxic payload into lung tissue as an off-target effect.22Molecular Cancer Therapeutics. Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution More recent murine models have implicated the specific chemical structure of the linker connecting the antibody to its drug as a contributor to lung injury, with certain cleavable linker designs producing more severe pathology.23npj precision oncology. Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease ILD is uncommon but potentially serious, and clinicians monitor patients closely for early respiratory symptoms.
Getting Antibodies Into the Brain
HER2-positive breast cancer has a particular tendency to metastasize to the brain, and treating those metastases has been a longstanding problem. The blood-brain barrier, a tightly sealed layer of cells that protects the brain, blocks most large molecules, including standard antibodies like trastuzumab, from entering in meaningful concentrations. ADCs may have an advantage here. Research has identified a specific transporter protein called the neonatal Fc receptor (FcRn), present on the endothelial cells of the blood-tumor barrier, that can actively shuttle antibodies across the barrier and into brain tumors. Blocking this transporter in mouse models significantly reduced the amount of drug reaching brain metastases and weakened the antitumor effect, confirming that the transport is receptor-driven rather than passive leaking.24Neuro-Oncology. Mechanistic Basis and Translational Development of HER2 Antibody Drug Conjugates for HER2-Positive Breast Cancer Brain Metastases
In xenograft models of brain metastases, HER2-targeted ADCs showed uptake in tumor deposits even when passive permeability markers indicated the barrier was largely intact, reinforcing the idea that active transport rather than barrier breakdown explains how the drugs get in.25PubMed Central. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker These findings have practical implications: they suggest that ADCs can reach brain metastases through a mechanism that older HER2 antibodies could not exploit as efficiently, potentially changing the treatment landscape for patients with brain involvement.
CAR-T Cells and Cellular Approaches to HER2
Beyond injectable antibodies and ADCs, researchers are engineering the patient’s own immune cells to recognize HER2. In CAR-T therapy, a patient’s T cells are collected, genetically modified to express a receptor that recognizes HER2, and then infused back. The modified cells can seek out and destroy HER2-expressing cancer cells without needing an external antibody.
The major safety concern with HER2 CAR-T cells is that HER2 is not exclusive to cancer. Normal tissues, including the heart, lungs, and gastrointestinal tract, express low levels of HER2. An overly aggressive CAR-T cell could attack those tissues, causing serious toxicity. One promising solution is to use CAR-T cells with a deliberately lower binding affinity for HER2. In mouse studies, low-affinity HER2 CAR-T cells could distinguish between tumor cells packed with HER2 and normal tissue with low HER2 levels, killing the former while sparing the latter.26Journal for ImmunoTherapy of Cancer. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity Another approach uses a switchable system where CAR-T cells only become active in the presence of a separate adapter molecule that bridges the T cell to the HER2 target. By tuning the binding strength of that adapter molecule, researchers have demonstrated selective killing of HER2-overexpressing breast cancer cells with little damage to cells expressing HER2 at normal levels, and complete tumor eradication in animal models.27Journal of Clinical Oncology. Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy Both strategies are still in early development, but they reflect a broader effort to bring the power of cellular immunotherapy to solid tumors without the collateral damage that has so far limited its use outside blood cancers.
Cost, Biosimilars, and Access
The success of HER2 antibodies has raised a practical question: who can actually afford them? Trastuzumab was among the first biologic cancer drugs, and its cost has been a barrier in many parts of the world. The expiration of trastuzumab’s patents opened the door for biosimilars, which are near-identical copies manufactured by different companies at lower prices. Several trastuzumab biosimilars have been approved and are in clinical use globally.
Even so, cost remains an issue, especially in low- and middle-income countries. An economic evaluation in Thailand, for instance, found that while biosimilar trastuzumab improved affordability compared to the original, it still was not considered cost-effective at prevailing prices. The study concluded that targeted price negotiation and policy measures would be needed to make access genuinely sustainable.28PubMed. Economic Evaluation and Budget Impact of Biosimilar Trastuzumab for HER2-Positive Metastatic Breast Cancer in Thailand Newer agents like T-DXd and pertuzumab, which remain under patent, are substantially more expensive and have no biosimilar alternatives yet, making the gap between what is medically possible and what is widely accessible a continuing tension in HER2-positive cancer care.
The development arc of HER2-targeted therapy, from the approval of trastuzumab in the late 1990s through today’s ADCs, bispecific antibodies, and CAR-T strategies, established a template that oncology has followed ever since: identify a molecular target, build a diagnostic to find patients who have it, and develop drugs that exploit it.29PubMed Central. Twenty-five years with HER2 targeted therapy That model of drug-diagnostic co-development, born from the HER2 story, now shapes how virtually every new targeted cancer therapy is brought to patients.